S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Evelo Biosciences Stock Forecast, Price & News

+0.42 (+5.12%)
(As of 11/30/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
229,838 shs
Average Volume
262,049 shs
Market Capitalization
$460.83 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive EVLO News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Evelo Biosciences logo

About Evelo Biosciences

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases; EDP2939 for inflammation; and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.


Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down to $10.95
November 10, 2021 |  americanbankingnews.com
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $12.00
November 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.64 per share


Net Income
$-93.67 million
Pretax Margin




Free Float
Market Cap
$460.83 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.99 out of 5 stars

Medical Sector

616th out of 1,390 stocks

Pharmaceutical Preparations Industry

286th out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

Is Evelo Biosciences a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Evelo Biosciences stock.
View analyst ratings for Evelo Biosciences
or view top-rated stocks.

How has Evelo Biosciences' stock price been impacted by Coronavirus (COVID-19)?

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EVLO shares have increased by 97.3% and is now trading at $8.62.
View which stocks have been most impacted by COVID-19

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Evelo Biosciences

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) announced its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.63) EPS for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.09. During the same quarter last year, the firm posted ($0.45) EPS.
View Evelo Biosciences' earnings history

What price target have analysts set for EVLO?

6 equities research analysts have issued 12 month target prices for Evelo Biosciences' shares. Their forecasts range from $12.00 to $41.50. On average, they anticipate Evelo Biosciences' stock price to reach $21.92 in the next twelve months. This suggests a possible upside of 154.3% from the stock's current price.
View analysts' price targets for Evelo Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the following people:
  • Simba Gill, President, Chief Executive Officer & Director
  • Luca Scavo, Chief Financial Officer, Treasurer & Senior VP
  • Mark Bodmer, Chief Scientific Officer, President-R&D
  • Andrea Itano, Senior Vice President & Head-Research
  • Duncan McHale, Chief Medical Officer

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Credit Suisse AG (6.19%), BlackRock Inc. (3.44%), State of Michigan Retirement System (2.06%), Geode Capital Management LLC (0.97%), Millennium Management LLC (0.00%) and Citadel Advisors LLC (0.00%). Company insiders that own Evelo Biosciences stock include David R Epstein, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends for Evelo Biosciences

Which major investors are selling Evelo Biosciences stock?

EVLO stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, California State Teachers Retirement System, Marshall Wace LLP, New York State Common Retirement Fund, The Manufacturers Life Insurance Company , BlackRock Inc., and Larson Financial Group LLC.
View insider buying and selling activity for Evelo Biosciences
or view top insider-selling stocks.

Which major investors are buying Evelo Biosciences stock?

EVLO stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Credit Suisse AG, State of Michigan Retirement System, Citadel Advisors LLC, Belvedere Trading LLC, Cinctive Capital Management LP, Geode Capital Management LLC, and Morgan Stanley. Company insiders that have bought Evelo Biosciences stock in the last two years include David R Epstein, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Evelo Biosciences
or or view top insider-buying stocks.

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $8.62.

How much money does Evelo Biosciences make?

Evelo Biosciences has a market capitalization of $460.83 million. The company earns $-93.67 million in net income (profit) each year or ($2.39) on an earnings per share basis.

How many employees does Evelo Biosciences have?

Evelo Biosciences employs 2,018 workers across the globe.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is www.evelobio.com.

Where are Evelo Biosciences' headquarters?

Evelo Biosciences is headquartered at 620 Memorial Drive Suite 500 West, Cambridge MA, 02139.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at (617) 577-0300 or via email at [email protected].

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]at.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.